4-甲基-2-(4-三氟甲基苯基)噻唑-5-羧酸 | 144059-86-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲基-2-(4-三氟甲基苯基)噻唑-5-羧酸
• 中文别名: 2-(4'-三氟甲基苯基)-4-甲基噻唑-5-甲酸；4-甲基-2-[4-(三氟甲基)苯基]三唑-5-羧酸；2-(4-三氟甲基苯基)-4-甲基噻唑-5-甲酸
• 英文名称: 4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carboxylic acid
• 英文别名: 4-methyl-2-(4-(trifluoromethyl)phenyl)thiazole-5-carboxylic acid；4-methyl-2-[4-(trifluoromethyl)phenyl]-l,3-thiazole-5-carboxylic acid
• CAS: 144059-86-9
• 化学式: C₁₂H₈F₃NO₂S
• mdl: MFCD00068105
• 分子量: 287.262
• InChiKey: DRFFZMPSUPHSJN-UHFFFAOYSA-N

物化性质

• 熔点：
  237 °C
• 沸点：
  413.2±55.0 °C(Predicted)
• 密度：
  1.438±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934100090
• 安全说明：
  S22,S36/37/39

SDS

Name:	4-Methyl-2-[4-(trifluoromethyl)phenyl]-1 3-thiazole-5-carboxylic Material Safety Data Sheet
Synonym:
CAS:	144059-86-9

Section 1 - Chemical Product MSDS Name:4-Methyl-2-[4-(trifluoromethyl)phenyl]-1 3-thiazole-5-carboxylic Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
144059-86-9	4-Methyl-2-[4-(trifluoromethyl)phenyl]	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 144059-86-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white crystalline solid
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 238 - 241 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H8F3NO2S
Molecular Weight: 287

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 144059-86-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 144059-86-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 144059-86-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 144059-86-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

4-甲基-2-(4-三氟甲基苯基)-1,3-噻唑-5-羧酸是GW 501516（HY-10838）的代谢产物。

反应信息

• 作为反应物：
  描述：

  4-甲基-2-(4-三氟甲基苯基)噻唑-5-羧酸 在 硼烷四氢呋喃络合物 、 甲基磺酰氯 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 5-(氯甲基)-4-甲基-2-[4-(三氟甲基)苯基]-1,3-噻唑
  参考文献：
  名称：

  Oxadiazolones, processes for their preparation and their use as pharmaceuticals

  摘要：

  公开号：

  EP1586573B1
• 作为产物：
  描述：

  4-(三氟甲基)硫代苯甲酰胺 在 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 35.0h， 生成 4-甲基-2-(4-三氟甲基苯基)噻唑-5-羧酸
  参考文献：
  名称：

  基于片段的筛选在大肠杆菌DsbA抑制剂设计中的应用

  摘要：

  巯基二硫键氧化还原酶DsbA催化革兰氏阴性细菌周质中二硫键的形成。DsbA底物包括与细菌毒力有关的蛋白质。在缺乏DsbA的情况下，许多这些蛋白质无法正确折叠，从而使细菌无毒。因此，DsbA是毒力的关键介质，抑制剂可以充当抗毒剂。已采用生物物理筛选来鉴定与大肠杆菌中DsbA结合的片段。这些片段之一的加工产生了在体外抑制DsbA活性的化合物。在基于细胞的测定中，这些化合物抑制细菌运动，但对液体培养中的生长没有影响，这与对DsbA的选择性抑制相一致。与DsbA结合的抑制剂的晶体结构表明它们与活性位点相邻结合。总之，数据表明DsbA可能适合于通过抑制细菌毒力起作用的新型抗菌化合物。

  DOI：

  10.1002/anie.201410341

文献信息

• Inhibitors of cathepsin S
  申请人：IRM LLC

  公开号：US20040198780A1

  公开（公告）日：2004-10-07

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了用于选择性抑制蛋白酶S的化合物、组合物和方法。在一个优选方面，当至少存在另一种蛋白酶同工酶（例如，蛋白酶K）时，选择性地抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S来治疗受试者疾病状态的方法。
• Inhibitors of histone deacetylase
  申请人：——

  公开号：US20020177594A1

  公开（公告）日：2002-11-28

  Compounds having the formula 1 or therapeutically acceptable salts thereof, are histone deacetylase (HDAC) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

  具有以下化学式的化合物或其治疗上可接受的盐是组蛋白去乙酰化酶（HDAC）抑制剂。本文揭示了该化合物的制备、含有该化合物的组合物以及使用该化合物治疗疾病的方法。
• Decarboxylative Cross-Coupling of Azoyl Carboxylic Acids with Aryl Halides
  作者：Fengzhi Zhang、Michael F. Greaney

  DOI：10.1021/ol1019597

  日期：2010.11.5

  Decarboxylative cross-coupling of thiazole and oxazole-5-carboxylic acids with aryl halides is reported. Under a bimetallic system of catalytic palladium and a stoichiometric silver carbonate, a variety of (hetero)arylated azoles can be prepared in excellent yield.

  据报道噻唑和恶唑-5-羧酸与芳基卤的脱羧交叉偶联。在催化钯和化学计量的碳酸银的双金属体系下，可以以高收率制备各种（杂）芳基化的唑。
• Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist
  作者：Lijun Hu、Qiang Ren、Liming Deng、Zongtao Zhou、Zongyu Cai、Bin Wang、Zheng Li

  DOI：10.1016/j.ejmech.2020.113106

  日期：2021.2

  Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent

  法尼醇X受体（FXR）是胆汁酸激活的核受体，调节胆汁酸和脂质的代谢，并维持内部环境的稳定性。FXR被认为是肝脏疾病（如药物性肝损伤，脂肪肝和胆汁淤积症）的治疗目标。先前报道的FXR部分激动剂6就其高强度和低分子大小而言是一种合适的先导化合物，而化合物6的对接研究则显示了一个较大的未占据的疏水口袋，这可能为结构活性关系提供了更多可能性（SAR ）学习。在这项研究中，我们基于铅化合物6进行了全面的SAR和分子建模研究。所有这些努力导致鉴定出一系列新的FXR部分激动剂。在该系列中，化合物41表现出最佳的活性，并且与FXR的结合口袋有很强的相互作用。此外，化合物41通过调节FXR相关基因的表达并提高抗氧化能力，保护小鼠免受对乙酰氨基酚诱导的肝毒性。总之，这些结果表明化合物41是一种有前途的FXR部分激动剂，适合进一步研究。
• [EN] PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS<br/>[FR] COMPOSES DE PIPERIDINE PHENYLE A SUBSTITUTION PHENYLE S'UTILISANT COMME ACTIVATEURS DE PPAR
  申请人：PFIZER PROD INC

  公开号：WO2004048334A1

  公开（公告）日：2004-06-10

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPARα激动剂，含有这类化合物的药物组合物以及利用这类化合物提高特定血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他特定血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中的应用。